The Quantellect read.As of Nov 19, 2026, 14 active firms cover Madrigal Pharmaceuticals Inc: 13 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $542.00 to $962.00, a moderate spread. The average target of $696.64 sits 75% above the current $398.55. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 12 to 13 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.79 next quarter toward $11.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS14 active firms
Buy
Strong Buy00%
Buy1393%
Neutral17%
Sell00%
Strong Sell00%
Based on 14 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$696.64
+74.8% upside
Average target across 14 active firms as of Nov 19, 2026 vs $398.55 current
Highest Target$962.00
Average Target$696.64
Lowest Target$542.00
Detailed analyst forecasts for MDGL
Showing 1–14 of 14 named analysts shown · 14 active firms in the rating projection
As of Nov 19, 2026, 13 of 14 active firms rate MDGL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
MDGL EPS & revenue forecast
EPS · NEXT QUARTER
$0.79
Range $-0.39 – $1.97 · 2 analysts · -157% YoY
Next period, 2 analysts expect Madrigal Pharmaceuticals Inc to earn $0.79 a share (range $-0.39 – $1.97), versus $-1.38 a year earlier. Full-year consensus is $-2.00, growing to $11.21 the year after.
REVENUE · NEXT QUARTER
$459.0M
Range $425.1M – $468.4M · 2 analysts · +47% YoY
Revenue is expected to reach $459.0M (range $425.1M – $468.4M), +47.4% year-over-year. Full-year consensus is $1.6B, rising to $2.2B next year.
Top analysts covering Madrigal Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDGL.
#1
Mayank Mamtani
B. Riley Securities · Rank #36
Buy
$560.00+40.5% to target
Overall win rate
49%
+ Follow
#2
Jonathan Wolleben
JMP Securities · Rank #54
Buy
$739.00+85.4% to target
Overall win rate
43%
+ Follow
#3
Andrew Fein
HC Wainwright & Co. · Rank #73
Buy
$620.00+55.6% to target
Overall win rate
45%
+ Follow
#4
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$612.00+53.6% to target
Overall win rate
44%
+ Follow
#5
Yasmeen Rahimi
Piper Sandler · Rank #339
Buy
$900.00+125.8% to target
Overall win rate
30%
+ Follow
MDGL stock forecast FAQ
What is MDGL's average 12-month price target?+
The 14 active firms with a live target average $696.64 for Madrigal Pharmaceuticals Inc over the next 12 months, ranging from a $962.00 high to a $542.00 low, as of Nov 19, 2026.
Is MDGL stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 14 active firms as of Nov 19, 2026, 13 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for MDGL?+
The Street-high target is $962.00 (Barclays), and the Street-low is $542.00 (B of A Securities). The average of all 14 active-firm targets is $696.64.
How many active Wall Street firms cover MDGL?+
14 active firms have a recognized rating on Madrigal Pharmaceuticals Inc as of Nov 19, 2026, and 14 active firms carry a live 12-month price target.
Who is the most accurate analyst covering MDGL?+
Among analysts who currently cover MDGL, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #36). Their current call is Buy with a $560.00 target.
What is Madrigal Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.79 per share (range $-0.39 – $1.97) across 2 analysts. Full-year EPS is projected at $-2.00, rising to $11.21 the following year.
How much revenue is Madrigal Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $459.0M (range $425.1M – $468.4M). Full-year revenue is projected at $1.6B, growing to $2.2B next year.
Have analysts been upgrading or downgrading MDGL lately?+
As of Nov 19, 2026, 13 of 14 active firms rate MDGL a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDGL calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.